Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Corrensstraße 48, 48149, Münster, Germany.
Cells-in-Motion Cluster of Excellence (EXC 1003-CiM), Westfälische Wilhelms-Universität Münster, Germany.
ChemMedChem. 2018 Mar 6;13(5):446-452. doi: 10.1002/cmdc.201700810. Epub 2018 Feb 16.
Because only a few studies have investigated the affinity and functional activity of NMDA receptor open channel blockers under the same assay conditions, a comparative study of common open channel blockers is of major interest. The pharmacological activities of MK-801, phencyclidine (PCP), dexoxadrol, etoxadrol, (S)- and (R)-ketamine, dextromethorphan, memantine, and amantadine were analyzed under uniform assay conditions. Affinity toward the PCP and ifenprodil binding sites was recorded in radioligand binding assays. GluN2A and GluN2B subtype-specific cytoprotective activity was determined in lactate dehydrogenase (LDH) assays. The data were correlated with published IC values obtained in two-electrode voltage clamp experiments. A high correlation was found between PCP affinity, ion flux inhibition, and cytoprotective activity. The channel blockers were classified into four groups showing high, moderate, low, and very low potency. Some of the open channel blockers display unexpected subtype selectivity. The comparative study allows the characterization of open channel blockers from their receptor ligand interaction via inhibition of ion flux up to overall cytoprotective activity. The subtype preference of some open channel blockers will stimulate the development of novel subtype-selective open channel blockers with decreased side effect potential.
由于只有少数研究在相同的测定条件下研究了 NMDA 受体开放通道阻滞剂的亲和力和功能活性,因此对常见开放通道阻滞剂进行比较研究具有重要意义。在统一的测定条件下分析了 MK-801、苯环利定(PCP)、右旋氧苯丙胺、右苯丙胺、(S)-和(R)-氯胺酮、右美沙芬、美金刚和金刚烷胺的药理学活性。在放射配体结合测定中记录了对 PCP 和ifenprodil 结合位点的亲和力。在乳酸脱氢酶(LDH)测定中确定了 GluN2A 和 GluN2B 亚型特异性细胞保护活性。将数据与在双电极电压钳实验中获得的已发表的 IC 值相关联。在 PCP 亲和力、离子通量抑制和细胞保护活性之间发现了高度相关性。通道阻滞剂被分为显示高、中、低和非常低效力的四个组。一些开放通道阻滞剂显示出出乎意料的亚型选择性。比较研究允许从受体配体相互作用通过抑制离子通量到整体细胞保护活性来表征开放通道阻滞剂。一些开放通道阻滞剂的亚型偏好将刺激具有降低副作用潜力的新型亚型选择性开放通道阻滞剂的开发。
Psychopharmacology (Berl). 2003-11
Pharmacol Res Perspect. 2019-6-20
Korean J Physiol Pharmacol. 2025-3-1
Eur Arch Psychiatry Clin Neurosci. 2023-10
Front Cell Neurosci. 2022-7-22
Anesth Pain Med. 2021-6-29
J Neural Transm (Vienna). 2019-7-17